Change in C-reactive protein levels and FEV1 decline: A longitudinal population-based study

Respiratory Medicine

Volumn 100, Issue 12, 2006, Pages 2112-2120

  Shaaban, Rafea ^a   Kony, Sabine ^a   Driss, Fathi ^b   Leynaert, Bénédicte ^a   Soussan, David ^a   Pin, Isabelle ^c   Neukirch, Françoise ^a   Zureik, Mahmoud ^a  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

C reactive protein; Epidemiology; Forced expiratory volume in 1 s; Longitudinal study

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; ASTHMA; BIOASSAY; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FRANCE; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MALE; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS;

ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; FRANCE; HEALTH SURVEYS; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; SMOKING; SWITZERLAND;

EID: 33751064909     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.03.027     Document Type: Article

References (43)

1. Hole D.J., Watt G.C., Davey-Smith G., Hart C.L., Gillis C.R., and Hawthorne V.M. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 313 (1996) 711-715
2. 1 and peripheral blood leukocyte count to total mortality. The normative aging study. Am J Epidemiol 142 (1995) 493-498
3. Lange P., Nyboe J., Appleyard M., Jensen G., and Schnohr P. Spirometric findings and mortality in never-smokers. J Clin Epidemiol 43 (1990) 867-873
4. Kannel W.B., Hubert H., and Lew E.A. Vital capacity as a predictor of cardiovascular disease: the Framingham study. Am Heart J 105 (1983) 311-315
5. Griffith K.A., Sherrill D.L., Siegel E.M., Manolio T.A., Bonekat H.W., and Enright P.L. Predictors of loss of lung function in the elderly. The cardiovascular health study. Am J Respir Crit Care Med 163 (2001) 61-68
6. Zureik M., Benetos A., Neukirch C., Courbon D., Bean K., Thomas F., et al. Reduced pulmonary function is associated with central arterial stiffness in men. Am J Respir Crit Care Med 164 (2001) 2181-2185
7. Zureik M., Kauffmann F., Touboul P.-J., Courbon D., and Ducimetière P. Association between peak expiratory flow and the development of carotid atherosclerotic plaques. Arch Intern Med 161 (2001) 1669-1676
8. Bhatt D.L., and Topol E.J. Need to test the arterial inflammation hypothesis. Circulation 106 (2002) 136-140
9. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
10. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
11. 1, wheezing, bronchial hyper-responsiveness and allergy. Clin Exp Allergy 21 (1991) 669-674
12. Dahl M., Tybjaerg-Hansen A., Vesto J., Lange P., and Nordestgaard B.G. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 1008-1011
13. Leff A.R., and Antileukotriene Working Group. Discovery of leukotrienes and development of antileukotriene agents. Ann Allergy Asthma Immunol 86 (2001) 4-8
14. Jousilahti P., Salomaa V., Hakala K., Rasi V., Vahtera E., and Palosuo T. The association of sensitive systemic inflammation markers with bronchial asthma. Ann Allergy Asthma Immunol 89 (2002) 381-385
15. Koenig W. Inflammation and coronary heart disease: an overview. Cardiol Rev 9 (2001) 31-35
16. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
17. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
18. Engström G., Lind P., Hedblad B., Wollmer P., Stavenow L., Janzon L., et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 106 (2002) 2555-2560
19. Barnes P.J., Shapiro S.D., and Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22 (2003) 672-688
20. Kony S., Zureik M., Driss F., Neukirch C., Leynaert B., and Neukirch F. Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax 59 (2004) 892-896
21. Mendall M., Patel P., Ballam L., Strachan D., and Northfield T. C-reactive protein and its relation to cardiovascular risk factors: a population-based cross-sectional study. Br Med J 312 (1996) 1061-1065
22. Quanjer Ph H., and Tammeling G J. Standardized lung function. Bull Eur Physiopathol Resp 19 (1983) 7-10
23. Sherman C.B., Xu X., Speizer F.E., Ferris Jr. B.G., Weiss S.T., and Dockery D.W. Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 146 (1992) 855-859
24. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
25. Schols A.M., Creutzberg E.C., Buurman W.A., Campfield L.A., Saris W.H., and Wouters E.F. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) 1220-1226
26. Lewington S., Thomsen T., Davidsen M., Sherliker P., and Clarke R. Regression dilution bias in blood total and high-density lipoprotein cholesterol and blood pressure in the Glostrup and Framingham prospective studies. J Cardiovasc Risk 10 (2003) 143-148
27. Burney P.G.J., Luczynska C., Chinn S., and Jarvis D for the European Community Respiratory Health Survey. The European Community Respiratory Health Survey. Eur Respir J 7 (1994) 954-960
28. The European Community Respiratory Health Survey II Steering Committee. The European Community Respiratory Health Survey II. Eur Respir J 20 (2002) 1071-1079
29. Lazarus R., Sparrow D., and Weiss S.T. Effects of obesity and fat distribution on ventilatory function: the normative aging study. Chest 111 (1997) 891-898
30. Mendall M.A., Strachan D.P., Butland B.K., Ballam L., Morris J., Sweetnam P.M., et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 21 (2000) 1584-1590
31. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 343 (2000) 269-280
32. Celermajer D.S., Adams M.R., Clarkson P., Robinson J., McCredie R., Donald A., et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 334 (1996) 150-154
33. Raitakari O.T., Adams M.R., McCredie R.J., Griffiths K.A., and Celermajer D.S. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. Ann Intern Med 130 (1999) 578-581
34. Tracy R., Macy E., Bovill E.G., Cushman M., Cornell E.S., and Kuller L.H. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Bio 17 (1997) 2167-2176
35. Jane M., Gould, and Jeffrey N. Weiser expression of C-reactive protein in the human respiratory tract. Infect Immun 69 (2001) 1747-1754
36. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 8 (1990) 253-278
37. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S., and GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163 (2001) 1256-1276
38. Eid A.A., Ionescu A.A., Nixon L.S., Lewis-Jenkins V., Matthews S.B., Griffiths T.L., et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 1414-1418
39. 10). Am J Respir Crit Care Med 164 (2001) 826-830
40. Sin D.D., Lacy P., York E., and Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 760-765
41. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenic significance. Am J Respir Crit Care Med 155:1187-205.
42. Gauldie J., Richards C., Harnish D., Lansdorp P., and Baumann H. Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute-phase protein response in liver cells. Proc Natl Acad Sci USA 84 (1987) 7251-7255
43. Gauldie J., Richards C., Northemann W., Fey G., and Baumann H. IFNB2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute-phase gene regulation in hepatocytes. Ann NY Acad Sci 557 (1989) 46-59